LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

NCT01041040 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloblastic Leukemia

Interventions

DRUG: gemtuzumab

Sponsor

PETHEMA Foundation